Powered by bioaccess®
Global Trial Accelerators™
Global Trial Accelerators™
Fast-Tracking First-in-Human Trials, Anywhere Hosted by bioaccess® CEO, Julio G. Martínez-Clark and Business Development Director Jesus E. Moreno, the Global Trial Accelerators™ podcast (formerly known as LATAM Medtech Leaders) delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia. What You’ll Learn: Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN. Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance. Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites. Why Listen? Actionable Playbooks: Reverse-engineer success stories from startups that enrolled cohorts 50% faster and secured Series B funding 12–18 months early. Regulatory Intel: Stay ahead of shifting guidelines in LATAM, Eastern Europe, and APAC with on-the-ground experts. Future-Proof Insights: Explore decentralized trials, AI-driven recruitment, and post-trial commercialization in $1B+ markets. “bioaccess®’s Serbia site activated in 8 weeks-9 months faster than our EU delay. This podcast is why we partnered with them.” – Digital Health Startup CEO New episodes drop weekly. Subscribe to unlock your shortcut to global trial velocity. Brought to you by bioaccess® – Turning “anywhere” into accelerated FDA/EMA submissions since 2010.
Choose your favorite podcast player
Over 30,000 LinkedIn followers!

Fast-Tracking First-in-Human Trials, Anywhere

The Global Trial Accelerators™ podcast (formerly known as LATAM Medtech Leaders) delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia.

Recent

Oct. 30, 2025

David Kraemer, Founder & Managing Member at 10 || 2 Capital Partners

In this episode, we sit down with David M. Kraemer, Founder of a boutique investment bank and former Vice President at Merrill Lynch and Wilshire Consulting. With deep experience across public and private markets, David shares insights on capital formation, innovation, and navigating complex invest…

Listen to the Episode
Oct. 16, 2025

David Kraemer, Founder & Managing Member at 10 || 2 Capital Partners

In this episode, we sit down with David Kraemer, Founder of a boutique investment bank and former Vice President at Merrill Lynch and Wilshire Consulting. With deep experience across investment banking, venture capital, biotech, AI, and emerging technologies, David shares insights on capital forma…

Watch the Video
Oct. 15, 2025

Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc

In this episode, we sit down with Dr. Joseph M. Palumbo, a physician-scientist, mentor, and therapeutics developer with over three decades of leadership in psychiatry, neurology, and neurodegenerative research. Dr. Palumbo has held senior roles as Global Head of Psychiatry at Johnson & Johnson, Vi…

Watch the Video
Oct. 9, 2025

Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc

In this episode, we sit down with Dr. Joseph M. Palumbo, a physician-scientist, mentor, and therapeutics developer with over three decades of leadership in psychiatry, neurology, and neurodegenerative research. Dr. Palumbo has held senior roles as Global Head of Psychiatry at Johnson & Johnson, Vi…

Watch the Video
Oct. 9, 2025

Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc

Dr. Palumbo is a physician-scientist with 30+ years leading programs in psychiatry, neurology, and neurodegenerative disease across Johnson & Johnson/Janssen, Mitsubishi Tanabe, Zynerba, and BioVie, with contributions to FDA registrations such as Risperdal Consta, Invega, Invega Sustenna, and Radic…

Listen to the Episode
Sept. 26, 2025

Nicholas Kadysh, CEO at PharmAla Biotech

In this episode, we sit down with Nicholas Kadysh, CEO of PharmAla Biotech, the company pioneering GMP MDMA production and recognized as the top-performing stock on the Canadian capital markets in 2023 by The Market Herald. As Chair of Psychedelics Canada, Nicholas has played a pivotal role in str…

Watch the Video

Recent Blog Posts

Nov. 12, 2025

Building a Winning Team: David Kraemer's Perspective on Talent Acquis…

In today's fast-paced business environment, building a high-performing team is paramount to achieving sustainable success. Nowhere is this truer than in the demanding world of private equity, where the stakes are high and the pressure to deliver exc…

Read the Blog Post
Oct. 11, 2025

Dr. Joseph Palumbo's Journey: From Psychiatry to Neurodegenerative Re…

Welcome to the blog! In this post, we'll be exploring the extraordinary career of Dr. Joseph Palumbo, a true pioneer in the fields of psychiatry, neurology, and neurodegenerative research. From his early work to his current role at BioVie, Dr. Palum…

Read the Blog Post
Oct. 4, 2025

PharmAla Biotech: Leading the Charge in GMP MDMA Production

Welcome to this blog post, a companion piece to our recent podcast episode featuring Nicholas Kadysh, CEO of PharmAla Biotech. In this episode, which you can listen to here, we delved into PharmAla Biotech's groundbreaking work in revolutionizing GM…

Read the Blog Post

About the Hosts

Julio G Martinez-Clark Profile Photo

Julio G Martinez-Clark

CEO, bioaccess®

Julio G. Martinez-Clark, CEO of bioaccess®, has spent over a decade dismantling barriers to Medtech, Biopharma, and Radiopharma innovation by positioning Latin America, Eastern Europe (the Balkans), and Australia as global leaders in clinical research. His work challenges entrenched perceptions of the region, transforms healthcare access for underserved populations, and reimagines how medical innovations reach commercialization. Through bioaccess®, Julio has created a blueprint for cost-effective, ethically rigorous clinical trials that accelerate time-to-market while elevating local communities.

Jesus E. Moreno Profile Photo

Jesus E. Moreno

Business Development Director, bioaccess®

Jesus E. Moreno is a business development director who provides efficient and reliable clinical research services in Latin America. With a passion for driving innovation in the healthcare sector, Jesus leverages his bilingual biomedical engineering background and his understanding of the unique challenges that Medtech startups face to provide valuable support and deliver accelerated clinical study results. Jesus profoundly understands the critical role that reliable and streamlined clinical research plays in the success of Medtech startups. He firmly believes that by offering cost-effective solutions without compromising quality, Medtech startups can achieve their clinical goals faster and make a meaningful impact in the healthcare industry. Jesus is passionate about supporting Medtech startups in their journey towards bringing innovative medical technologies to market. Jesus possesses the technical expertise to understand the complexities of medical devices and technologies. This knowledge enables him to identify tailored solutions that meet the specific needs of Medtech startups. Jesus has a bachelor's degree in biomedical engineering and a master's degree in electronics engineering.